Clinical Implications of Naples Prognostic Score for Patients with Resected Cholangiocarcinoma: A Real-World Experience

被引:4
|
作者
Xu, Benjie [1 ]
Zhu, Jiahao [1 ]
Wang, Ren [1 ]
Pang, Xiangyi [1 ]
Wang, Xin [1 ]
Lian, Jie [1 ,2 ]
Lu, Haibo [1 ,2 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Outpatient Chemotherapy, Harbin, Peoples R China
[2] Harbin Med Univ, Canc Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Naples prognostic score; cholangiocarcinoma; nomogram; overall survival; real-world experience; INFLAMMATION;
D O I
10.2147/JIR.S446735
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: The Nutritional Prognostic Score (NPS) is a composite indicator that effectively reflects the preoperative nutritional and inflammation status of patients. Its prognostic value has been extensively confirmed in various types of tumors. Our study aims to investigate the clinical implications of the NPS in the postoperative patients with cholangiocarcinoma (CCA). Patients and Methods: Data on clinicopathological characteristics were collected from CCA patients who underwent radical surgery between 2014 and 2019 at Harbin Medical University Cancer Hospital. NPS was calculated using relevant indicators to categorize the patients, and association of NPS with clinicopathological characteristics and survival outcomes were analyzed. To assess differences in survival rates between different groups, we utilized the Kaplan -Meier method. Independent prognostic risk factors were identified by Cox regression analysis. A CONomogram was created, and its accuracy in survival prediction was evaluated using receiver operating characteristic (ROC) curves. Independent verification was conducted in the validation group. Results: For this study, a cohort of 232 patients was enlisted and subsequently divided into training group (N=162) and validation group (N=70). An evident correlation was detected between NPS and preoperative malnutrition. Patients with higher NPS exhibited a worse overall survival (OS), with 5 -year OS rates of 79.1%, 33.1%, and 10.6%. Multivariate analysis revealed that NPS was an independent risk factor for OS in resected CCA patients (P<0.001). The NPS-based Nomogram was developed to accurately assess the risk of patients. Conclusion: The NPS was identified as a significant risk factor that impacts the prognosis of patients with resected CCA. In order to improve prognosis management, the NPS-based Nomogram has been demonstrated to be a precise and efficient tool.
引用
收藏
页码:655 / 667
页数:13
相关论文
共 50 条
  • [41] A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia
    Di Taranto, Maria Donata
    Giacobbe, Carola
    Buonaiuto, Alessio
    Calcaterra, Ilenia
    Palma, Daniela
    Maione, Giovanna
    Iannuzzo, Gabriella
    Di Minno, Matteo Nicola Dario
    Rubba, Paolo
    Fortunato, Giuliana
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [42] Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma
    Omar Abdel-Rahman
    Jennifer Spratlin
    Sheryl Koski
    Medical Oncology, 2021, 38
  • [43] Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma
    Abdel-Rahman, Omar
    Spratlin, Jennifer
    Koski, Sheryl
    MEDICAL ONCOLOGY, 2021, 38 (02)
  • [44] Real-World Experience with Ofatumumab
    Thomas, K.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 202 - 203
  • [45] Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
    Zhang, Jing
    Ji, Chao
    Cheng, Bo
    Ruan, Shi-Fan
    Liu, Tao
    Huang, Jin-Wen
    CHINESE MEDICAL JOURNAL, 2020, 133 (24) : 3020 - 3022
  • [46] Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
    Zhang Jing
    Ji Chao
    Cheng Bo
    Ruan Shi-Fan
    Liu Tao
    Huang Jin-Wen
    中华医学杂志英文版, 2020, 133 (24) : 3020 - 3022
  • [47] Real-world experience - Reply
    Hutchinson, D
    CHEMICAL ENGINEERING PROGRESS, 1998, 94 (03) : 8 - 8
  • [48] Real-World Experience with Ocrelizumab
    Moss, Brandon P.
    Utigard, Erica
    Baldassari, Laura E.
    Cohen, Jeffrey A.
    Ontaneda, Daniel D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 69 - 70
  • [49] Real-world experience with ocrelizumab
    Moss, B.
    Parrotta, E.
    Baldassari, L.
    Planchon, S.
    Cohen, J.
    Ontaneda, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 780 - 781
  • [50] Real-World Experience with Ocrelizumab
    Moss, Brandon P.
    Utigard, Erica
    Baldassari, Laura E.
    Cohen, Jeffrey A.
    Ontaneda, Daniel D.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31